CAJ | 학술논문

2012年6月1日至5日,第48届美国临床肿瘤学会( ASCO)年会在美国芝加哥举行,大会探讨了多发性骨髓瘤(MM)的危险分层治疗.MM具有较大的异质性,根据危险分层对患者进行治疗具有重要意义.根据细胞遗传学异常可将患者分为标危、中危和高危3组.标危患者可采用4周期的Rd方案(来那度胺+地塞米松)或VCD方案(硼替佐米+环磷酰胺+地塞米松)进行诱导治疗；中危患者可采用4周期的VCD方案进行诱导治疗；高危患者可采用4周期的VRD方案(硼替佐米+来那度胺+地塞米松)进行诱导治疗.诱导治疗结束后,可进行白体造血干细胞移植或巩固维持治疗.患者年龄、一般状况和合并疾病是决定是否适合自体造血干细胞移植的关键因素.
2012년6월1일지5일,제48계미국림상종류학회( ASCO)년회재미국지가가거행,대회탐토료다발성골수류(MM)적위험분층치료.MM구유교대적이질성,근거위험분층대환자진행치료구유중요의의.근거세포유전학이상가장환자분위표위、중위화고위3조.표위환자가채용4주기적Rd방안(래나도알+지새미송)혹VCD방안(붕체좌미+배린선알+지새미송)진행유도치료；중위환자가채용4주기적VCD방안진행유도치료；고위환자가채용4주기적VRD방안(붕체좌미+래나도알+지새미송)진행유도치료.유도치료결속후,가진행백체조혈간세포이식혹공고유지치료.환자년령、일반상황화합병질병시결정시부괄합자체조혈간세포이식적관건인소.
The 48th annual meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago from June 1-5 2012 and the risk-adapted therapy of multiple myeloma (MM) was discussed.MM is a heterogeneous disease and all patients should be accepted risk-adapted therapy. According to cytogenetic abnormalities, MM patients are divided into three groups,standard risk, intermediate risk and high risk.Patients with standard risk may received 4 cycles Rd regimes (lenalidomide plus low dose dexamethasone) or VCD regimes (bortezomib,cyclophosphamide,dexamethasone) for induction therap.Patients with intermediate risk may received 4 cycles VCD regimes for induction therapy.Patients with high risk may received 4 cycles VRD regimes (bortezomib,lenalidomide,dexamethasone) for induction therapy.After induction treatment,patients can received autologous hematopoietic cell transplantation or consolidation/maintenance therapy. The determination of which patients are eligible for autologous hematopoietic cell transplantation according age,comorbidities and performance status.